SPORTY: Physical Activity and Cardiovascular Profile of Pre-conceptional Women at Risk for GHD

Sponsor
Hasselt University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05888467
Collaborator
(none)
140
1
3
17.8
7.8

Study Details

Study Description

Brief Summary

To compare the cardiovascular profile of pre-conceptional women at risk for developing Gestational Hypertensive Disorders in subsequent pregnancy before and after physical activity.

Condition or Disease Intervention/Treatment Phase
  • Other: supervised infrared exercise group
  • Other: supervised non-infrared exercise group
  • Other: Control group
N/A

Detailed Description

The SPORTY trial hypothesizes that exercise improves the cardiovascular (CV) profile of pre-conceptional women at risk for developing gestational hypertensive disorders (GHD) in subsequent pregnancy in a profile-specific way.

Research objectives:

The primary objective is to compare the complete CV profile before and after an exercise period of 6 and 12 weeks.

Secondary objectives are:
  • To correlate the exercise-induced changes in CV profile to the type, frequency and intensity of exercise.

  • To evaluate the added value of supervised and personalized training in inducing changes in the CV profile compared to non-supervised training.

  • To evaluate the added value of infrared light therapy during supervised training in inducing changes in the CV profile compared to non-infrared supervised training.

  • To assess how long the adaptations in the CV profile induced by supervised training last in case the supervision is halted.

Methodology:

All study participants who provided written informed consent and are eligible to participate in the study are 2:1:1 randomly assigned into a non-supervised exercise group (control), a supervised non-infrared exercise group (intervention), or a supervised infrared exercise group (intervention), stratified by baseline cardiac output (CO).

All study participants will undergo a CV profiling assessment at baseline, at week 6 visit, at week 12 visit, and at week 18 visit. The CV profile assessment is a standardized validated protocol consisting of a simple, non-invasive method using the combination of (1) electrocardiogram (ECG) with Doppler ultrasonography providing information about arteries and veins, (2) Bio-Impedance Spectrum Analysis (BI) using Maltron giving information about the fluid balance, and (3) Impedance Cardiography (ICG) using the NICCOMO registering heart parameters in supine and standing position. The CV profiling will be performed at UHasselt (building A) or at Ziekenhuis Oost-Limburg (Campus Sint-Jan) in the framework of the Limburg Clinical Research Center.

All participants are asked to complete the International Physical Activity Questionnaire (IPAQ) online in Castor EDC at home to report their baseline physical activity status. Demographics, clinical characteristics and medical history are obtained and reported in the eCRF.

For ethical reasons, all study groups will be advised to exercise for a period of 12 weeks, but only the two supervised exercise groups will receive a personalized and guided exercise plan. In addition, all participants will receive an activity diary and are asked to fill in their weekly exercise throughout the entire study period.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, monocentric, interventional, randomized-controlled trialProspective, monocentric, interventional, randomized-controlled trial
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The Impact of Physical Activity on the Cardiovascular Profile of Pre-conceptional Women at Risk for Developing Gestational Hypertensive Disorders in Subsequent Pregnancy.
Actual Study Start Date :
May 8, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Control group

non-supervised exercise group

Other: Control group
Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
Other Names:
  • non-supervised exercise group
  • Active Comparator: Intervention: supervised non-infrared exercise group

    supervised non-infrared exercise group

    Other: supervised infrared exercise group
    Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.

    Active Comparator: Intervention: supervised infrared exercise group

    supervised infrared exercise group

    Other: supervised non-infrared exercise group
    Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.

    Outcome Measures

    Primary Outcome Measures

    1. Change in cardiac output level from Baseline at week 12 visit [Baseline and week 12]

      Cardiac Output assessed via the NICCOMO

    Secondary Outcome Measures

    1. Change in arterial parameters from Baseline at week 12 visit [Baseline and week 12]

      arterial pulse transit time (APTT), pulsatility index (PI) and resistivity index (RI) of the left and right arcuate arteries

    2. Change in venous parameters from Baseline at week 12 visit [Baseline and week 12]

      enous pulse transit time (VPTT) of the hepatic and left and right renal veins, hepatic vein impedance index (HVI), and left and right renal interlobar vein impedance indices (RIVI)

    3. Change in cardiac parameters from Baseline at week 12 visit [Baseline and week 12]

      stroke volume (SV), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), pre-ejection period (PEP), total peripheral resistance (TPR), left ventricular ejection time (LVET), velocity and acceleration indices (VI and ACI)

    4. Change in body water volumes from Baseline at week 12 visit [Baseline and week 12]

      total body water (TBW), extracellular water (ECW), intracellular water (ICW), ratio ECW/ICW

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Women at risk for the development of GHD in subsequent pregnancy based on the presence of at least one of the following risk factors:

    • high body mass index (BMI>30 kg/m²)

    • a family history of PE (mother, sister)

    • in the need of assisted reproduction techniques in a previous or subsequent pregnancy

    • maternal comorbidities: prior PE, diabetes mellitus, chronic hypertension, chronic kidney disease or antiphospholipid syndrome

    • Non-pregnant (as confirmed by a negative pregnancy urine dipstick test)

    • Age ≥ 18 years

    • Being able to understand the Dutch language

    Exclusion Criteria:
    Participants eligible for this study must not meet any of the following criteria:
    • Pregnant at inclusion

    • Not being able to exercise according to physician's decision

    • Suffering from underlying diseases that can affect the CV profile such as oncological diseases coronary heart disease, aortic disease, peripheral arterial disease

    • Participating in another clinical study that may alter the results of this study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hasselt University Diepenbeek Limburg Belgium 3590

    Sponsors and Collaborators

    • Hasselt University

    Investigators

    • Principal Investigator: Dorien Lanssens, UHasselt

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Dorien Lanssens, Principal Investigator, Hasselt University
    ClinicalTrials.gov Identifier:
    NCT05888467
    Other Study ID Numbers:
    • SPORTY-01
    First Posted:
    Jun 5, 2023
    Last Update Posted:
    Jun 5, 2023
    Last Verified:
    May 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 5, 2023